U.S. stocks slumped on Tuesday under the weight of another jump for the price of oil. It was a return to form for financial ...

According to Adam Parker, founder of Trivariate Research, investors aiming for a defensive approach might want to look at ...

Referring to the impact of artificial intelligence, Andy Jassy tells employees, "We expect that this will reduce our total corporate workforce." TikTok Ban Will be Delayed Another 90 Days by Trump An ...

Asian shares were mixed and oil prices advanced Wednesday after the escalation of conflict in the Middle East hit Wall Street ...

US Big Pharma firm Eli Lilly & Co. agreed to buy gene-editing biotech company Verve Therapeutics Inc. for $1.3 billion as the ...

As of Tuesday's close, the S&P 500 fell 0.84% to 5,982.72 points; the Nasdaq Composite Index fell 0.91% to 19,521.09 points; and the Dow Jones Industrial Average fell 0.7% to 42,215.8 points. As a ...

Shares in Hong Kong-based Regencell Bioscience Holdings nearly quadrupled in value amid a 38-to-1 stock split despite the ...

Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...

NEW YORK (AP) — U.S. stocks are nudging lower on Tuesday, and oil prices are rising again. It’s a modest return to form for ...

U.S. stocks slumped on Tuesday under the weight of another jump for the price of oil. It was a return to form for financial markets after Wall Street's worries about Israel's fighting with Iran had ...

Eli Lilly & Co. aims to offer a one-and-done heart-disease medicine by paying up to $1.3 billion for Verve Therapeutics Inc., the maker of a new gene-editing treatment, Lilly said on Tuesday.